{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T04:52:16Z","timestamp":1794027136011,"version":"4.8.0"},"reference-count":176,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T00:00:00Z","timestamp":1748217600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011500","name":"Research Institute at Nationwide Children's Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011500","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.jcyt.2025.04.064","type":"journal-article","created":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T02:36:29Z","timestamp":1746844589000},"page":"812-825","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Dark NKnight rising: a current perspective on NK cell and CAR-NK cell therapy"],"prefix":"10.1016","volume":"27","author":[{"given":"Joseph R.","family":"Caporale","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2880-1796","authenticated-orcid":false,"given":"Meisam","family":"Naeimi Kararoudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9413-3637","authenticated-orcid":false,"given":"Margaret G.","family":"Lamb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6693-5392","authenticated-orcid":false,"given":"Dean A.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jcyt.2025.04.064_bib0001","first-page":"126","article-title":"Fresh cell therapy","volume":"41","year":"1991","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.jcyt.2025.04.064_bib0002","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1084\/jem.161.1.40","article-title":"Adoptive transfer studies demonstrating the antiviral effect of natural killer cells in vivo","volume":"161","author":"Bukowski","year":"1985","journal-title":"J Exp Med"},{"issue":"10","key":"10.1016\/j.jcyt.2025.04.064_bib0003","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41568-022-00491-0","article-title":"Natural killer cells in antitumour adoptive cell immunotherapy","volume":"22","author":"Laskowski","year":"2022","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"10.1016\/j.jcyt.2025.04.064_bib0004","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/s41577-022-00732-1","article-title":"Roles of natural killer cells in immunity to cancer, and applications to immunotherapy","volume":"23","author":"Wolf","year":"2023","journal-title":"Nat Rev Immunol"},{"issue":"5562","key":"10.1016\/j.jcyt.2025.04.064_bib0005","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1126\/science.1068440","article-title":"Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants","volume":"295","author":"Ruggeri","year":"2002","journal-title":"Science"},{"issue":"51","key":"10.1016\/j.jcyt.2025.04.064_bib0006","doi-asserted-by":"crossref","first-page":"20777","DOI":"10.1073\/pnas.1218913109","article-title":"E. Donnall Thomas (1920\u20132012)","volume":"109","author":"Blume","year":"2012","journal-title":"Proc Natl Acad Sci"},{"issue":"5","key":"10.1016\/j.jcyt.2025.04.064_bib0007","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jcyt.2025.04.064_bib0008","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/imr.12793","article-title":"Cellular therapy: Adoptive immunotherapy with expanded natural killer cells","volume":"290","author":"Lee","year":"2019","journal-title":"Immunol Rev"},{"issue":"1","key":"10.1016\/j.jcyt.2025.04.064_bib0009","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1182\/blood-2004-12-4797","article-title":"Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells","volume":"106","author":"Imai","year":"2005","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.jcyt.2025.04.064_bib0010","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S0092-8674(00)80453-5","article-title":"Identification of Clonogenic Common Lymphoid Progenitors in Mouse Bone Marrow","volume":"91","author":"Kondo","year":"1997","journal-title":"Cell"},{"issue":"13","key":"10.1016\/j.jcyt.2025.04.064_bib0011","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1182\/blood-2009-08-236398","article-title":"Single-cell analysis of the common lymphoid progenitor compartment reveals functional and molecular heterogeneity","volume":"115","author":"Mansson","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2025.04.064_bib0012","series-title":"Advances in Immunology","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/bs.ai.2015.12.006","article-title":"Chapter Seven - Adoptive T-Cell Therapy for Cancer","author":"Yang","year":"2016"},{"issue":"8","key":"10.1016\/j.jcyt.2025.04.064_bib0013","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood-2012-07-442558","article-title":"Comparison of primary human cytotoxic T-cell and natural killer cell responses reveal similar molecular requirements for lytic granule exocytosis but differences in cytokine production","volume":"121","author":"Chiang","year":"2013","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jcyt.2025.04.064_bib0014","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.it.2014.11.001","article-title":"NK cells regulating T cell responses: mechanisms and outcome","volume":"36","author":"Crouse","year":"2015","journal-title":"Trends Immunol"},{"key":"10.1016\/j.jcyt.2025.04.064_bib0015","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.clim.2016.06.013","article-title":"Adoptive transfer of natural killer cells promotes the anti-tumor efficacy of T cells","volume":"177","author":"Goding","year":"2017","journal-title":"Clin Immunol"},{"issue":"8","key":"10.1016\/j.jcyt.2025.04.064_bib0016","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1002\/eji.200939435","article-title":"Natural killer cells remember: An evolutionary bridge between innate and adaptive immunity?","volume":"39","author":"Sun","year":"2009","journal-title":"Eur J Immunol"},{"issue":"633","key":"10.1016\/j.jcyt.2025.04.064_bib0017","doi-asserted-by":"crossref","first-page":"eabm1375","DOI":"10.1126\/scitranslmed.abm1375","article-title":"Hematopoietic cell transplantation donor-derived memory-like NK cells functionally persist after transfer into patients with leukemia","volume":"14","author":"Berrien-Elliott","year":"2022","journal-title":"Sci Transl Med"},{"issue":"1","key":"10.1016\/j.jcyt.2025.04.064_bib0018","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/j.1600-065X.1997.tb00959.x","article-title":"Use of adoptive transfer of T-cell antigen-receptor-transgenic T cells for the study of T-cell activation in vivo","volume":"156","author":"Pape","year":"1997","journal-title":"Immunol Rev"},{"key":"10.1016\/j.jcyt.2025.04.064_bib0019","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1600-065X.1988.tb00771.x","article-title":"Antigen processing for presentation to T lymphocytes: function, mechanisms, and implications for the T-cell repertoire","volume":"106","author":"Berzofsky","year":"1988","journal-title":"Immunol Rev"},{"issue":"6055","key":"10.1016\/j.jcyt.2025.04.064_bib0020","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/319675a0","article-title":"Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy","volume":"319","author":"Karre","year":"1986","journal-title":"Nature"},{"key":"10.1016\/j.jcyt.2025.04.064_bib0021","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1146\/annurev.cb.06.110190.002155","article-title":"The T cell antigen receptor: insights into organelle biology","volume":"6","author":"Klausner","year":"1990","journal-title":"Annu Rev Cell Biol"},{"issue":"36","key":"10.1016\/j.jcyt.2025.04.064_bib0022","doi-asserted-by":"crossref","first-page":"13139","DOI":"10.1073\/pnas.1409155111","article-title":"Diversity and clonal selection in the human T-cell repertoire","volume":"111","author":"Qi","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"10.1016\/j.jcyt.2025.04.064_bib0023","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1002\/bies.20812","article-title":"Involvement of IL-2 in homeostasis of regulatory T cells: the IL-2 cycle","volume":"30","author":"Yarkoni","year":"2008","journal-title":"BioEssays"},{"issue":"10","key":"10.1016\/j.jcyt.2025.04.064_bib0024","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/nri3044","article-title":"NK cell development, homeostasis and function: parallels with CD8+ T cells","volume":"11","author":"Sun","year":"2011","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"10.1016\/j.jcyt.2025.04.064_bib0025","doi-asserted-by":"crossref","first-page":"299","DOI":"10.4049\/jimmunol.162.1.299","article-title":"IL-2 Induces STAT4 Activation in Primary NK Cells and NK Cell Lines, But Not in T Cells1","volume":"162","author":"Wang","year":"1999","journal-title":"J Immunol"},{"issue":"5","key":"10.1016\/j.jcyt.2025.04.064_bib0026","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.immuni.2017.10.008","article-title":"The Broad Spectrum of Human Natural Killer Cell Diversity","volume":"47","author":"Freud","year":"2017","journal-title":"Immunity"},{"issue":"12","key":"10.1016\/j.jcyt.2025.04.064_bib0027","doi-asserted-by":"crossref","first-page":"4480","DOI":"10.4049\/jimmunol.136.12.4480","article-title":"The relationship of CD16 (Leu-11) and Leu-19 (NKH-1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes","volume":"136","author":"Lanier","year":"1986","journal-title":"J Immunol"},{"issue":"8","key":"10.1016\/j.jcyt.2025.04.064_bib0028","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1038\/s41590-024-01883-0","article-title":"High-dimensional single-cell analysis of human natural killer cell heterogeneity","volume":"25","author":"Rebuffet","year":"2024","journal-title":"Nat Immunol"},{"issue":"11","key":"10.1016\/j.jcyt.2025.04.064_bib0029","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1038\/s41590-022-01327-7","article-title":"Clonal expansion and epigenetic inheritance of long-lasting NK cell memory","volume":"23","author":"R\u00fcckert","year":"2022","journal-title":"Nat Immunol"},{"issue":"1","key":"10.1016\/j.jcyt.2025.04.064_bib0030","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1182\/blood-2005-04-1351","article-title":"Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion","volume":"107","author":"Bryceson","year":"2006","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jcyt.2025.04.064_bib0031","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/imr.12015","article-title":"Dynamics of NK cell interactions in vivo","volume":"251","author":"Deguine","year":"2013","journal-title":"Immunol Rev"},{"issue":"1","key":"10.1016\/j.jcyt.2025.04.064_bib0032","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/j.1600-065X.1997.tb00946.x","article-title":"Killer cell inhibitory receptors: diversity, specificity, and function","volume":"155","author":"Long","year":"1997","journal-title":"Immunol Rev"},{"issue":"4","key":"10.1016\/j.jcyt.2025.04.064_bib0033","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1002\/1521-4141(200104)31:4<1076::AID-IMMU1076>3.0.CO;2-Y","article-title":"Role of NKG2D in tumor cell lysis mediated by human NK cells: cooperation with natural cytotoxicity receptors and capability of recognizing tumors of nonepithelial origin","volume":"31","author":"Pende","year":"2001","journal-title":"Eur J Immunol"},{"issue":"7","key":"10.1016\/j.jcyt.2025.04.064_bib0034","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1002\/eji.202049028","article-title":"Human NK cells, their receptors and function","volume":"51","author":"Quatrini","year":"2021","journal-title":"Eur J Immunol"},{"issue":"7","key":"10.1016\/j.jcyt.2025.04.064_bib0035","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/0167-5699(90)90097-S","article-title":"In search of the 'missing self': MHC molecules and NK cell recognition","volume":"11","author":"Ljunggren","year":"1990","journal-title":"Immunol Today"},{"issue":"2","key":"10.1016\/j.jcyt.2025.04.064_bib0036","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.jaci.2022.09.022","article-title":"Human natural killer cells: Form, function, and development","volume":"151","author":"Mace","year":"2023","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.jcyt.2025.04.064_bib0037","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0030264","article-title":"Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells","volume":"7","author":"Denman","year":"2012","journal-title":"PLoS One"},{"issue":"20","key":"10.1016\/j.jcyt.2025.04.064_bib0038","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14205046","article-title":"Immune Checkpoint Blockade: A Strategy to Unleash the Potential of Natural Killer Cells in the Anti-Cancer Therapy","volume":"14","author":"Grottoli","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jcyt.2025.04.064_bib0039","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.omto.2021.11.016","article-title":"Natural killer cells and immune-checkpoint inhibitor therapy: Current knowledge and new challenges","volume":"24","author":"Poggi","year":"2022","journal-title":"Mol Ther Oncolytics"},{"key":"10.1016\/j.jcyt.2025.04.064_bib0040","article-title":"Clinical application and prospect of immune checkpoint inhibitors for CAR-NK cell in tumor immunotherapy","volume":"13","author":"Yang","year":"2022","journal-title":"Front Immunol"},{"issue":"11","key":"10.1016\/j.jcyt.2025.04.064_bib0041","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1016\/j.ccell.2024.09.010","article-title":"The hallmarks of cancer immune evasion","volume":"42","author":"Galassi","year":"2024","journal-title":"Cancer Cell"},{"issue":"16","key":"10.1016\/j.jcyt.2025.04.064_bib0042","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25168899","article-title":"Cracking the Codes behind Cancer Cells' Immune Evasion","volume":"25","author":"Mundhara","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jcyt.2025.04.064_bib0043","article-title":"Tumor evasion from T cell surveillance","volume":"2011","author":"T\u00f6pfer","year":"2011","journal-title":"J Biomed Biotechnol"},{"issue":"1","key":"10.1016\/j.jcyt.2025.04.064_bib0044","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s40425-018-0367-1","article-title":"Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA)","volume":"6","author":"Danaher","year":"2018","journal-title":"Journal for ImmunoTherapy of Cancer"},{"issue":"1","key":"10.1016\/j.jcyt.2025.04.064_bib0045","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1096\/fj.14-250985","article-title":"VEGF suppresses T-lymphocyte infiltration in the tumor microenvironment through inhibition of NF-\u03baB-induced endothelial activation","volume":"29","author":"Huang","year":"2015","journal-title":"FASEB J"},{"issue":"11","key":"10.1016\/j.jcyt.2025.04.064_bib0046","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1016\/j.celrep.2019.08.017","article-title":"Natural Killer Cells Suppress T Cell-Associated Tumor Immune Evasion","volume":"28","author":"Freeman","year":"2019","journal-title":"Cell Rep"},{"issue":"1","key":"10.1016\/j.jcyt.2025.04.064_bib0047","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1182\/blood-2006-10-049072","article-title":"Proteolytic processing of CXCL11 by CD13\/aminopeptidase N impairs CXCR3 and CXCR7 binding and signaling and reduces lymphocyte and endothelial cell migration","volume":"110","author":"Proost","year":"2007","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jcyt.2025.04.064_bib0048","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.coi.2011.12.009","article-title":"Targeting the PD-1\/B7-H1(PD-L1) pathway to activate anti-tumor immunity","volume":"24","author":"Topalian","year":"2012","journal-title":"Curr Opin Immunol"},{"issue":"21","key":"10.1016\/j.jcyt.2025.04.064_bib0049","doi-asserted-by":"crossref","first-page":"5689","DOI":"10.1158\/1078-0432.CCR-20-1065","article-title":"Immune Escape After Adoptive T-cell Therapy for Malignant Gliomas","volume":"26","author":"Wildes","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jcyt.2025.04.064_bib0050","article-title":"Bright future or blind alley? CAR-T cell therapy for solid tumors","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.jcyt.2025.04.064_bib0051","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.cell.2014.12.033","article-title":"Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity","volume":"160","author":"Rooney","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.jcyt.2025.04.064_bib0052","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.3389\/fimmu.2017.01061","article-title":"Potentiation of Natural Killer Cells for Cancer Immunotherapy: A Review of Literature","volume":"8","author":"Lowry","year":"2017","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.jcyt.2025.04.064_bib0053","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41572-023-00438-1","article-title":"Acute graft-versus-host disease","volume":"9","author":"Malard","year":"2023","journal-title":"Nat Rev Dis Primers"},{"issue":"5","key":"10.1016\/j.jcyt.2025.04.064_bib0054","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1182\/blood-2014-07-592881","article-title":"Acute GVHD in patients receiving IL-15\/4-1BBL activated NK cells following T-cell\u2013depleted stem cell transplantation","volume":"125","author":"Shah","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2025.04.064_bib0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115888","article-title":"The paths and challenges of \u201coff-the-shelf\u201d CAR-T cell therapy: An overview of clinical trials","volume":"169","author":"Moradi","year":"2023","journal-title":"Biomed Pharmacother"},{"issue":"11","key":"10.1016\/j.jcyt.2025.04.064_bib0056","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1200\/JCO.21.01755","article-title":"Naive T-Cell Depletion to Prevent Chronic Graft-Versus-Host Disease","volume":"40","author":"Bleakley","year":"2022","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.jcyt.2025.04.064_bib0057","doi-asserted-by":"crossref","first-page":"250.e1","DOI":"10.1016\/j.jtct.2022.02.008","article-title":"A Phase I Study to Determine the Maximum Tolerated Dose of ex Vivo Expanded Natural Killer Cells Derived from Unrelated, HLA-Disparate Adult Donors","volume":"28","author":"Otegbeye","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"21","key":"10.1016\/j.jcyt.2025.04.064_bib0058","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1182\/blood-2009-05-222190","article-title":"NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effects","volume":"115","author":"Olson","year":"2010","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jcyt.2025.04.064_bib0059","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1182\/blood-2017-05-780668","article-title":"NK cell recovery after haploidentical HSCT with posttransplant cyclophosphamide: dynamics and clinical implications","volume":"131","author":"Russo","year":"2018","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.jcyt.2025.04.064_bib0060","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1002\/ajh.27281","article-title":"Results of a phase I trial with Haploidentical mbIL-21 ex vivo expanded NK cells for patients with multiply relapsed and refractory AML","volume":"99","author":"Ciurea","year":"2024","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1016\/j.jcyt.2025.04.064_bib0061","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1182\/blood-2014-07-592881","article-title":"Acute GVHD in patients receiving IL-15\/4-1BBL activated NK cells following T-cell-depleted stem cell transplantation","volume":"125","author":"Shah","year":"2015","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jcyt.2025.04.064_bib0062","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1038\/leu.2015.260","article-title":"CD56dimCD57+NKG2C+ NK cell expansion is associated with reduced leukemia relapse after reduced intensity HCT","volume":"30","author":"Cichocki","year":"2016","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.jcyt.2025.04.064_bib0063","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1182\/blood-2004-07-2974","article-title":"Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer","volume":"105","author":"Miller","year":"2005","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.jcyt.2025.04.064_bib0064","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1200\/JCO.2009.24.4590","article-title":"NKAML: A Pilot Study to Determine the Safety and Feasibility of Haploidentical Natural Killer Cell Transplantation in Childhood Acute Myeloid Leukemia","volume":"28","author":"Rubnitz","year":"2010","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.jcyt.2025.04.064_bib0065","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1172\/JCI24480","article-title":"Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells","volume":"115","author":"Gattinoni","year":"2005","journal-title":"J Clin Invest"},{"issue":"41","key":"10.1016\/j.jcyt.2025.04.064_bib0066","doi-asserted-by":"crossref","first-page":"17469","DOI":"10.1073\/pnas.0907448106","article-title":"Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity","volume":"106","author":"Hinrichs","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"10.1016\/j.jcyt.2025.04.064_bib0067","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J Clin Invest"},{"issue":"6","key":"10.1016\/j.jcyt.2025.04.064_bib0068","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: what we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"issue":"8","key":"10.1016\/j.jcyt.2025.04.064_bib0069","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1182\/blood.2021011532","article-title":"Systemic IL-15 promotes allogeneic cell rejection in patients treated with natural killer cell adoptive therapy","volume":"139","author":"Berrien-Elliott","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2025.04.064_bib0070","doi-asserted-by":"crossref","first-page":"3854","DOI":"10.1182\/blood-2021-149989","article-title":"Gda-201, a Novel Metabolically Enhanced Allogeneic Natural Killer (NK) Cell Product Yields High Remission Rates in Patients with Relapsed\/Refractory Non-Hodgkin Lymphoma (NHL): 2-Year Survival and Correlation with Cytokine IL7","volume":"138","author":"Bachanova","year":"2021","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.jcyt.2025.04.064_bib0071","doi-asserted-by":"crossref","DOI":"10.1172\/JCI154334","article-title":"Expansion, persistence, and efficacy of donor memory-like NK cells infused for posttransplant relapse","volume":"132","author":"Shapiro","year":"2022","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jcyt.2025.04.064_bib0072","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2023.101073","article-title":"Advances in NK cell therapy for hematologic malignancies: NK source, persistence and tumor targeting","volume":"60","author":"Merino","year":"2023","journal-title":"Blood Rev"},{"issue":"13","key":"10.1016\/j.jcyt.2025.04.064_bib0073","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1182\/bloodadvances.2018028332","article-title":"First-in-human trial of rhIL-15 and haploidentical natural killer cell therapy for advanced acute myeloid leukemia","volume":"3","author":"Cooley","year":"2019","journal-title":"Blood Adv"},{"issue":"12","key":"10.1016\/j.jcyt.2025.04.064_bib0074","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003894","article-title":"Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities","volume":"9","author":"Christodoulou","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"2","key":"10.1016\/j.jcyt.2025.04.064_bib0075","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/leu.2017.226","article-title":"Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity","volume":"32","author":"Liu","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.jcyt.2025.04.064_bib0076","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1226518","article-title":"Engineering NK-CAR.19 cells with the IL-15\/IL-15Ralpha complex improved proliferation and anti-tumor effect in vivo","volume":"14","author":"Silvestre","year":"2023","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.jcyt.2025.04.064_bib0077","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.bbmt.2014.01.006","article-title":"Preactivation with IL-12, IL-15, and IL-18 induces CD25 and a functional high-affinity IL-2 receptor on human cytokine-induced memory-like natural killer cells","volume":"20","author":"Leong","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"10.1016\/j.jcyt.2025.04.064_bib0078","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1159\/000382019","article-title":"Human Cytokine-Induced Memory-Like Natural Killer Cells","volume":"7","author":"Berrien-Elliott","year":"2015","journal-title":"J Innate Immun"},{"issue":"11","key":"10.1016\/j.jcyt.2025.04.064_bib0079","doi-asserted-by":"crossref","DOI":"10.1172\/JCI154334","article-title":"Expansion, persistence, and efficacy of donor memory-like NK cells infused for posttransplant relapse","volume":"132","author":"Shapiro","year":"2022","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.jcyt.2025.04.064_bib0080","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13045-025-01669-3","article-title":"First-in-human evaluation of memory-like NK cells with an IL-15 super-agonist and CTLA-4 blockade in advanced head and neck cancer","volume":"18","author":"Shapiro","year":"2025","journal-title":"J Hematol Oncol"},{"issue":"11","key":"10.1016\/j.jcyt.2025.04.064_bib0081","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1172\/JCI90387","article-title":"CD56bright NK cells exhibit potent antitumor responses following IL-15 priming","volume":"127","author":"Wagner","year":"2017","journal-title":"J Clin Invest"},{"issue":"633","key":"10.1016\/j.jcyt.2025.04.064_bib0082","doi-asserted-by":"crossref","first-page":"eabm1375","DOI":"10.1126\/scitranslmed.abm1375","article-title":"Hematopoietic cell transplantation donor-derived memory-like NK cells functionally persist after transfer into patients with leukemia","volume":"14","author":"Berrien-Elliott","year":"2022","journal-title":"Sci Transl Med"},{"issue":"2","key":"10.1016\/j.jcyt.2025.04.064_bib0083","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.4049\/jimmunol.155.2.1000","article-title":"Chimeric zeta-receptors direct human natural killer (NK) effector function to permit killing of NK-resistant tumor cells and HIV-infected T lymphocytes","volume":"155","author":"Tran","year":"1995","journal-title":"J Immunol"},{"issue":"4","key":"10.1016\/j.jcyt.2025.04.064_bib0084","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1053\/j.seminhematol.2020.11.006","article-title":"Genetic and epigenetic modification of human primary NK cells for enhanced antitumor activity","volume":"57","author":"Kararoudi","year":"2020","journal-title":"Semin Hematol"},{"key":"10.1016\/j.jcyt.2025.04.064_bib0085","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.3389\/fimmu.2019.02873","article-title":"Efficient and Robust NK-Cell Transduction With Baboon Envelope Pseudotyped Lentivector","volume":"10","author":"Colamartino","year":"2019","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.jcyt.2025.04.064_bib0086","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ymthe.2019.10.009","article-title":"A Genetically Engineered Primary Human Natural Killer Cell Platform for Cancer Immunotherapy","volume":"28","author":"Pomeroy","year":"2020","journal-title":"Mol Ther"},{"issue":"4","key":"10.1016\/j.jcyt.2025.04.064_bib0087","doi-asserted-by":"crossref","DOI":"10.1016\/j.xpro.2021.100956","article-title":"Production of human CAR-NK cells with lentiviral vectors and functional assessment in vitro","volume":"2","author":"Portillo","year":"2021","journal-title":"STAR Protoc"},{"issue":"6","key":"10.1016\/j.jcyt.2025.04.064_bib0088","article-title":"Optimization and validation of CAR transduction into human primary NK cells using CRISPR and AAV","volume":"2","author":"Kararoudi","year":"2022","journal-title":"Cell Rep Methods"},{"issue":"4","key":"10.1016\/j.jcyt.2025.04.064_bib0089","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s00262-015-1761-x","article-title":"NK-92: an 'off-the-shelf therapeutic' for adoptive natural killer cell-based cancer immunotherapy","volume":"65","author":"Suck","year":"2016","journal-title":"Cancer Immunol Immunother"},{"issue":"3","key":"10.1016\/j.jcyt.2025.04.064_bib0090","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1080\/14653240310001523","article-title":"Ex vivo expansion of the highly cytotoxic human natural killer-92 cell-line under current good manufacturing practice conditions for clinical adoptive cellular immunotherapy","volume":"5","author":"Tam","year":"2003","journal-title":"Cytotherapy"},{"issue":"6","key":"10.1016\/j.jcyt.2025.04.064_bib0091","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/j.ymthe.2024.04.024","article-title":"Evolution of the clinical-stage hyperactive TcBuster transposase as a platform for robust non-viral production of adoptive cellular therapies","volume":"32","author":"Skeate","year":"2024","journal-title":"Mol Ther"},{"issue":"7","key":"10.1016\/j.jcyt.2025.04.064_bib0092","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1016\/j.ymthe.2024.05.022","article-title":"Engineering of potent CAR NK cells using non-viral Sleeping Beauty transposition from minimalistic DNA vectors","volume":"32","author":"Bexte","year":"2024","journal-title":"Mol Ther"},{"issue":"21","key":"10.1016\/j.jcyt.2025.04.064_bib0093","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1182\/blood.2020006200","article-title":"CD38 deletion of human primary NK cells eliminates daratumumab-induced fratricide and boosts their effector activity","volume":"136","author":"Kararoudi","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2025.04.064_bib0094","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1146\/annurev-immunol-101921-044122","article-title":"Designing Cancer Immunotherapies That Engage T Cells and NK Cells","volume":"41","author":"Kyrysyuk","year":"2023","journal-title":"Annu Rev Immunol"},{"issue":"11","key":"10.1016\/j.jcyt.2025.04.064_bib0095","doi-asserted-by":"crossref","first-page":"5058","DOI":"10.1182\/blood-2007-01-065383","article-title":"Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT","volume":"109","author":"Miller","year":"2007","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jcyt.2025.04.064_bib0096","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1182\/blood-2003-01-0091","article-title":"Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors","volume":"102","author":"Giebel","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2025.04.064_bib0097","doi-asserted-by":"crossref","first-page":"368","DOI":"10.3389\/fimmu.2015.00368","article-title":"NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in Cancer Immunotherapy","volume":"6","author":"Wang","year":"2015","journal-title":"Front Immunol"},{"issue":"9","key":"10.1016\/j.jcyt.2025.04.064_bib0098","doi-asserted-by":"crossref","first-page":"3260","DOI":"10.1172\/JCI62749","article-title":"Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment","volume":"122","author":"Tarek","year":"2012","journal-title":"J Clin Invest"},{"issue":"26","key":"10.1016\/j.jcyt.2025.04.064_bib0099","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.1200\/JCO.2011.41.3807","article-title":"Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission","volume":"30","author":"Cheung","year":"2012","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.jcyt.2025.04.064_bib0100","doi-asserted-by":"crossref","first-page":"9554","DOI":"10.1158\/0008-5472.CAN-10-2211","article-title":"Genotypes of NK cell KIR receptors, their ligands, and Fcgamma receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy","volume":"70","author":"Delgado","year":"2010","journal-title":"Cancer Res"},{"issue":"23","key":"10.1016\/j.jcyt.2025.04.064_bib0101","doi-asserted-by":"crossref","first-page":"7330","DOI":"10.1158\/1078-0432.CCR-09-1720","article-title":"KIR and HLA genotypes are associated with disease progression and survival following autologous hematopoietic stem cell transplantation for high-risk neuroblastoma","volume":"15","author":"Venstrom","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.jcyt.2025.04.064_bib0102","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/ni1582","article-title":"Functions of natural killer cells","volume":"9","author":"Vivier","year":"2008","journal-title":"Nat Immunol"},{"issue":"21","key":"10.1016\/j.jcyt.2025.04.064_bib0103","doi-asserted-by":"crossref","first-page":"6441","DOI":"10.1158\/1078-0432.CCR-17-0379","article-title":"A Pilot Trial of Humanized Anti-GD2 Monoclonal Antibody (hu14.18K322A) with Chemotherapy and Natural Killer Cells in Children with Recurrent\/Refractory Neuroblastoma","volume":"23","author":"Federico","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.jcyt.2025.04.064_bib0104","article-title":"Adoptive immunotherapy with haploidentical natural killer cells and Anti-GD2 monoclonal antibody m3F8 for resistant neuroblastoma: Results of a phase I study","volume":"7","author":"Modak","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jcyt.2025.04.064_bib0105","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/978-1-4939-3684-7_15","article-title":"Ex Vivo Expansion of Human NK Cells Using K562 Engineered to Express Membrane Bound IL21","volume":"1441","author":"Somanchi","year":"2016","journal-title":"Methods Mol Biol"},{"issue":"48","key":"10.1016\/j.jcyt.2025.04.064_bib0106","doi-asserted-by":"crossref","DOI":"10.3791\/2540","article-title":"Expansion, purification, and functional assessment of human peripheral blood NK cells","author":"Somanchi","year":"2011","journal-title":"J Vis Exp"},{"issue":"4","key":"10.1016\/j.jcyt.2025.04.064_bib0107","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1038\/leu.2014.246","article-title":"Cytotoxicity of CD56-positive lymphocytes against autologous B-cell precursor acute lymphoblastic leukemia cells","volume":"29","author":"Fei","year":"2015","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.jcyt.2025.04.064_bib0108","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1158\/1078-0432.CCR-12-1243","article-title":"Growth and activation of natural killer cells ex vivo from children with neuroblastoma for adoptive cell therapy","volume":"19","author":"Liu","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.jcyt.2025.04.064_bib0109","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0076781","article-title":"Antigen presenting cell-mediated expansion of human umbilical cord blood yields log-scale expansion of natural killer cells with anti-myeloma activity","volume":"8","author":"Shah","year":"2013","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.jcyt.2025.04.064_bib0110","doi-asserted-by":"crossref","first-page":"274","DOI":"10.5966\/sctm.2012-0084","article-title":"Clinical-scale derivation of natural killer cells from human pluripotent stem cells for cancer therapy","volume":"2","author":"Knorr","year":"2013","journal-title":"Stem Cells Transl Med"},{"issue":"3","key":"10.1016\/j.jcyt.2025.04.064_bib0111","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/bjh.14570","article-title":"Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma","volume":"177","author":"Shah","year":"2017","journal-title":"Br J Haematol"},{"issue":"16","key":"10.1016\/j.jcyt.2025.04.064_bib0112","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/blood-2017-05-785659","article-title":"Phase 1 clinical trial using mbIL21 ex vivo-expanded donor-derived NK cells after haploidentical transplantation","volume":"130","author":"Ciurea","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jcyt.2025.04.064_bib0113","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41375-021-01349-4","article-title":"Decrease post-transplant relapse using donor-derived expanded NK-cells","volume":"36","author":"Ciurea","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.jcyt.2025.04.064_bib0114","series-title":"The 44th Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians Oral Session, Bone Marrow Transplant","article-title":"Interim results of a phase 2 clinical trial using mb-IL21 ex vivo epxanded NK cells to enhance graft versus leukemia effect after haploidentical transplantation","author":"Ciurea","year":"2018"},{"issue":"10","key":"10.1016\/j.jcyt.2025.04.064_bib0115","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/j.jcyt.2017.07.008","article-title":"Phase 1 clinical trial of adoptive immunotherapy using \"off-the-shelf\" activated natural killer cells in patients with refractory and relapsed acute myeloid leukemia","volume":"19","author":"Boyiadzis","year":"2017","journal-title":"Cytotherapy"},{"issue":"51","key":"10.1016\/j.jcyt.2025.04.064_bib0116","doi-asserted-by":"crossref","first-page":"89256","DOI":"10.18632\/oncotarget.19204","article-title":"A phase I trial of NK-92 cells for refractory hematological malignancies relapsing after autologous hematopoietic cell transplantation shows safety and evidence of efficacy","volume":"8","author":"Williams","year":"2017","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/j.jcyt.2025.04.064_bib0117","first-page":"1083","article-title":"First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia","volume":"8","author":"Tang","year":"2018","journal-title":"Am J Cancer Res"},{"issue":"6669","key":"10.1016\/j.jcyt.2025.04.064_bib0118","doi-asserted-by":"crossref","DOI":"10.1038\/35739","article-title":"Signal sequences stop killer cells","volume":"391","author":"Long","year":"1998","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.jcyt.2025.04.064_bib0119","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/j.bbmt.2010.03.004","article-title":"Donor KIR Genes 2DL5A, 2DS1 and 3DS1 are associated with a reduced rate of leukemia relapse after HLA-identical sibling stem cell transplantation for acute myeloid leukemia but not other hematologic malignancies","volume":"16","author":"Stringaris","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6669","key":"10.1016\/j.jcyt.2025.04.064_bib0120","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1038\/35869","article-title":"HLA-E binds to natural killer cell receptors CD94\/NKG2A, B and C","volume":"391","author":"Braud","year":"1998","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.jcyt.2025.04.064_bib0121","doi-asserted-by":"crossref","first-page":"5082","DOI":"10.4049\/jimmunol.1201964","article-title":"Human cytomegalovirus (CMV)-induced memory-like NKG2C(+) NK cells are transplantable and expand in vivo in response to recipient CMV antigen","volume":"189","author":"Foley","year":"2012","journal-title":"J Immunol"},{"issue":"11","key":"10.1016\/j.jcyt.2025.04.064_bib0122","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1182\/blood-2011-10-386995","article-title":"Cytomegalovirus reactivation after allogeneic transplantation promotes a lasting increase in educated NKG2C+ natural killer cells with potent function","volume":"119","author":"Foley","year":"2012","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jcyt.2025.04.064_bib0123","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1038\/leu.2015.260","article-title":"CD56dimCD57+NKG2C+ NK cell expansion is associated with reduced leukemia relapse after reduced intensity HCT","volume":"30","author":"Cichocki","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.jcyt.2025.04.064_bib0124","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104343","article-title":"Comprehensive genetic and functional analyses of Fc gamma receptors influence on response to rituximab therapy for autoimmunity","volume":"86","author":"Robinson","year":"2022","journal-title":"EBioMedicine"},{"issue":"1","key":"10.1016\/j.jcyt.2025.04.064_bib0125","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s00251-017-1014-6","article-title":"QPY\/RAH haplotypes of the GZMB gene are associated with natural killer cell cytotoxicity","volume":"70","author":"Oboshi","year":"2018","journal-title":"Immunogenetics"},{"issue":"4","key":"10.1016\/j.jcyt.2025.04.064_bib0126","doi-asserted-by":"crossref","DOI":"10.4161\/onci.24185","article-title":"Human perforin mutations and susceptibility to multiple primary cancers","volume":"2","author":"Trapani","year":"2013","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jcyt.2025.04.064_bib0127","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1286750","article-title":"Charting a killer course to the solid tumor: strategies to recruit and activate NK cells in the tumor microenvironment","volume":"14","author":"Portillo","year":"2023","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.jcyt.2025.04.064_bib0128","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1002\/JLB.2MA0620-074R","article-title":"Drug target validation in primary human natural killer cells using CRISPR RNP","volume":"108","author":"Rautela","year":"2020","journal-title":"J Leukoc Biol"},{"issue":"136","key":"10.1016\/j.jcyt.2025.04.064_bib0129","article-title":"Generation of Knock-out Primary and Expanded Human NK Cells Using Cas9 Ribonucleoproteins","author":"Kararoudi","year":"2018","journal-title":"J Vis Exp"},{"issue":"9","key":"10.1016\/j.jcyt.2025.04.064_bib0130","doi-asserted-by":"crossref","first-page":"e246","DOI":"10.1002\/cpz1.246","article-title":"Ex Vivo Expansion and CRISPR-Cas9 Genome Editing of Primary Human Natural Killer Cells","volume":"1","author":"Huang","year":"2021","journal-title":"Curr Protoc"},{"issue":"5","key":"10.1016\/j.jcyt.2025.04.064_bib0131","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1038\/s41587-024-02282-4","article-title":"In vivo AAV-SB-CRISPR screens of tumor-infiltrating primary NK cells identify genetic checkpoints of CAR-NK therapy","volume":"43","author":"Peng","year":"2025","journal-title":"Nat Biotechnol"},{"issue":"8","key":"10.1016\/j.jcyt.2025.04.064_bib0132","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1182\/blood.2022016205","article-title":"Engineered and banked iPSCs for advanced NK- and T-cell immunotherapies","volume":"141","author":"Cichocki","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2025.04.064_bib0133","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.834002","article-title":"CRISPR Gene Editing of Human Primary NK and T Cells for Cancer Immunotherapy","volume":"12","author":"Elmas","year":"2022","journal-title":"Front Oncol"},{"issue":"2","key":"10.1016\/j.jcyt.2025.04.064_bib0134","doi-asserted-by":"crossref","first-page":"181-192 e5","DOI":"10.1016\/j.stem.2018.06.002","article-title":"Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor Activity","volume":"23","author":"Li","year":"2018","journal-title":"Cell Stem Cell"},{"issue":"12","key":"10.1016\/j.jcyt.2025.04.064_bib0135","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1038\/s41590-023-01659-y","article-title":"Forks in the road for CAR T and CAR NK cell cancer therapies","volume":"24","author":"Dagher","year":"2023","journal-title":"Nat Immunol"},{"issue":"5","key":"10.1016\/j.jcyt.2025.04.064_bib0136","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.114145","article-title":"Precision off-the-shelf natural killer cell therapies for oncology with logic-gated gene circuits","volume":"43","author":"Frankel","year":"2024","journal-title":"Cell Rep"},{"issue":"4","key":"10.1016\/j.jcyt.2025.04.064_bib0137","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/s41590-025-02103-z","article-title":"Enhancing human NK cell antitumor function by knocking out SMAD4 to counteract TGFbeta and activin A suppression","volume":"26","author":"Rea","year":"2025","journal-title":"Nat Immunol"},{"issue":"10","key":"10.1016\/j.jcyt.2025.04.064_bib0138","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1158\/2159-8290.CD-24-0096","article-title":"CD28 Costimulation Augments CAR Signaling in NK Cells via the LCK\/CD3zeta\/ZAP70 Signaling Axis","volume":"14","author":"Acharya","year":"2024","journal-title":"Cancer Discov"},{"issue":"4","key":"10.1016\/j.jcyt.2025.04.064_bib0139","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/s41423-024-01145-x","article-title":"Development of NK cell-based cancer immunotherapies through receptor engineering","volume":"21","author":"Page","year":"2024","journal-title":"Cell Mol Immunol"},{"issue":"6","key":"10.1016\/j.jcyt.2025.04.064_bib0140","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jcyt.2025.04.064_bib0141","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1038\/s41591-024-02826-w","article-title":"T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy","volume":"30","author":"Ghilardi","year":"2024","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.jcyt.2025.04.064_bib0142","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJMp2400209","article-title":"Secondary Cancers after Chimeric Antigen Receptor T-Cell Therapy","volume":"390","author":"Verdun","year":"2024","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jcyt.2025.04.064_bib0143","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009560","article-title":"Precision Enhancement of CAR-NK Cells through Non-Viral Engineering and Highly Multiplexed Base Editing","volume":"13","author":"Wang","year":"2025","journal-title":"J Immunother Cancer"},{"issue":"6","key":"10.1016\/j.jcyt.2025.04.064_bib0144","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/j.ymthe.2019.03.011","article-title":"Adoptive Transfer of NKG2D CAR mRNA-Engineered Natural Killer Cells in Colorectal Cancer Patients","volume":"27","author":"Xiao","year":"2019","journal-title":"Mol Ther"},{"issue":"6481","key":"10.1016\/j.jcyt.2025.04.064_bib0145","doi-asserted-by":"crossref","first-page":"eaba7365","DOI":"10.1126\/science.aba7365","article-title":"CRISPR-engineered T cells in patients with refractory cancer","volume":"367","author":"Stadtmauer","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.jcyt.2025.04.064_bib0146","unstructured":"Draft Guidance for Industry: Safety Testing of Human Allogeneic Cells Expanded for Use in Cell-Based Medical Products, in: U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research (CBER) (Ed.) FDA Maryland, 2024, pp. 1-12."},{"key":"10.1016\/j.jcyt.2025.04.064_bib0147","unstructured":"Guidance for Industry: Human Gene Therapy Products Incorporating Human Genome Editing, in: U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research (CBER) (Ed.) FDA Maryland, 2024, pp. 1-19."},{"key":"10.1016\/j.jcyt.2025.04.064_bib0148","unstructured":"Guidance for Industry: Considerations for the Development of Chimeric Antigen Receptor (CAR) T Cell Products, in: U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research (CBER) (Ed.) FDA Maryland, 2024, pp. 1-36."},{"issue":"1","key":"10.1016\/j.jcyt.2025.04.064_bib0149","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1182\/blood-2004-12-4797","article-title":"Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells","volume":"106","author":"Imai","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2025.04.064_bib0150","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-023-02785-8","article-title":"Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19","author":"Marin","year":"2024","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.jcyt.2025.04.064_bib0151","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1038\/s41591-023-02785-8","article-title":"Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19(+) B cell tumors: a phase 1\/2 trial","volume":"30","author":"Marin","year":"2024","journal-title":"Nat Med"},{"issue":"10473","key":"10.1016\/j.jcyt.2025.04.064_bib0152","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0140-6736(24)02462-0","article-title":"Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial","volume":"405","author":"Ghobadi","year":"2025","journal-title":"The Lancet"},{"key":"10.1016\/j.jcyt.2025.04.064_bib0153","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.886546","article-title":"Immunogenicity of CAR-T Cell Therapeutics: Evidence, Mechanism and Mitigation","volume":"13","author":"Khan","year":"2022","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.jcyt.2025.04.064_bib0154","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41587-020-0601-5","article-title":"Engineered off-the-shelf therapeutic T cells resist host immune rejection","volume":"39","author":"Mo","year":"2021","journal-title":"Nat Biotechnol"},{"issue":"Supplement 1","key":"10.1016\/j.jcyt.2025.04.064_bib0155","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2024-198684","article-title":"Safety and Efficacy of FT522, a First-in-Class, Multi-Antigen Targeted, Off-the-Shelf, iPSC-Derived CD19 CAR NK Cell Therapy with Alloimmune Defense Receptor (ADR) in Relapsed\/Refractory B-Cell Lymphoma","volume":"144","author":"Bachanova","year":"2024","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.jcyt.2025.04.064_bib0156","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.it.2022.08.004","article-title":"Harnessing IL-15 signaling to potentiate NK cell-mediated cancer immunotherapy","volume":"43","author":"Ma","year":"2022","journal-title":"Trends Immunol"},{"issue":"7","key":"10.1016\/j.jcyt.2025.04.064_bib0157","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1182\/blood-2014-02-556837","article-title":"Autonomous growth and increased cytotoxicity of natural killer cells expressing membrane-bound interleukin-15","volume":"124","author":"Imamura","year":"2014","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jcyt.2025.04.064_bib0158","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.96219","article-title":"Continuous treatment with IL-15 exhausts human NK cells via a metabolic defect","volume":"3","author":"Felices","year":"2018","journal-title":"JCI Insight"},{"issue":"7","key":"10.1016\/j.jcyt.2025.04.064_bib0159","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1158\/1078-0432.CCR-17-2451","article-title":"A First-in-Human Phase I Study of Subcutaneous Outpatient Recombinant Human IL15 (rhIL15) in Adults with Advanced Solid Tumors","volume":"24","author":"Miller","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"Supplement 1","key":"10.1016\/j.jcyt.2025.04.064_bib0160","article-title":"CD33 CAR T-Cells (CD33CART) for Children and Young Adults with Relapsed\/Refractory AML: Dose-Escalation Results from a Phase I\/II Multicenter Trial","volume":"142","author":"Shah","year":"2023","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.jcyt.2025.04.064_bib0161","doi-asserted-by":"crossref","first-page":"3282","DOI":"10.1038\/s41375-021-01232-2","article-title":"Autologous CD33-CAR-T cells for treatment of relapsed\/refractory acute myelogenous leukemia","volume":"35","author":"Tambaro","year":"2021","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.jcyt.2025.04.064_bib0162","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40164-024-00592-6","article-title":"Safety and efficacy of CD33-targeted CAR-NK cell therapy for relapsed\/refractory AML: preclinical evaluation and phase I trial","volume":"14","author":"Huang","year":"2025","journal-title":"Exp Hematol Oncol"},{"key":"10.1016\/j.jcyt.2025.04.064_bib0163","unstructured":"Senti Bio Announces Positive Initial Clinical Data in Phase 1 Clinical Trial of SENTI-202, a Logic Gated, Selective CD33\/FLT3-Targeting CAR-NK Cell Therapy for the Treatment of Relapsed\/Refractory Hematologic Malignancies Including AML, https:\/\/investors.sentibio.com\/news-releases\/news-release-details\/senti-bio-announces-positive-initial-clinical-data-phase-1, (accessed April 2, 2024)."},{"issue":"1","key":"10.1016\/j.jcyt.2025.04.064_bib0164","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/cei.13403","article-title":"Expression profiling of single cells and patient cohorts identifies multiple immunosuppressive pathways and an altered NK cell phenotype in glioblastoma","volume":"200","author":"Close","year":"2020","journal-title":"Clin Exp Immunol"},{"issue":"12","key":"10.1016\/j.jcyt.2025.04.064_bib0165","doi-asserted-by":"crossref","first-page":"7335","DOI":"10.4049\/jimmunol.172.12.7335","article-title":"Elevated TGF-beta1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients","volume":"172","author":"Lee","year":"2004","journal-title":"J Immunol"},{"issue":"14","key":"10.1016\/j.jcyt.2025.04.064_bib0166","doi-asserted-by":"crossref","DOI":"10.1172\/JCI142116","article-title":"Targeting the alphav integrin\/TGF-beta axis improves natural killer cell function against glioblastoma stem cells","volume":"131","author":"Shaim","year":"2021","journal-title":"J Clin Invest"},{"issue":"3","key":"10.1016\/j.jcyt.2025.04.064_bib0167","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109432","article-title":"Generation of glucocorticoid-resistant SARS-CoV-2 T cells for adoptive cell therapy","volume":"36","author":"Basar","year":"2021","journal-title":"Cell Rep"},{"issue":"1","key":"10.1016\/j.jcyt.2025.04.064_bib0168","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13045-025-01677-3","article-title":"CAR-NK cell therapy: latest updates from the 2024 ASH annual meeting","volume":"18","author":"Kong","year":"2025","journal-title":"J Hematol Oncol"},{"issue":"4","key":"10.1016\/j.jcyt.2025.04.064_bib0169","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1080\/10428194.2024.2438802","article-title":"Natural killer cells: a new promising source for developing chimeric antigen receptor anti-cancer cells in hematological malignancies","volume":"66","author":"Mousavi","year":"2025","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.jcyt.2025.04.064_bib0170","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2024.2415187","article-title":"Chimeric antigen receptor-natural killer (CAR-NK) cell immunotherapy: A bibliometric analysis from 2004 to 2023","volume":"20","author":"Li","year":"2024","journal-title":"Hum Vaccin Immunother"},{"issue":"2","key":"10.1016\/j.jcyt.2025.04.064_bib0171","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/bjh.19939","article-title":"Advances and challenges in chimeric antigen receptor-natural killer cell immunotherapy for cancer","volume":"206","author":"Rafei","year":"2025","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.jcyt.2025.04.064_bib0172","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s40164-025-00633-8","article-title":"The clinical landscape of CAR NK cells","volume":"14","author":"Jorgensen","year":"2025","journal-title":"Exp Hematol Oncol"},{"issue":"8","key":"10.1016\/j.jcyt.2025.04.064_bib0173","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-Cell Therapy in Autoimmune Disease - A Case Series with Follow-up","volume":"390","author":"M\u00fcller","year":"2024","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.jcyt.2025.04.064_bib0174","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41584-024-01139-z","article-title":"Advancements and challenges in CAR T cell therapy in autoimmune diseases","volume":"20","author":"Schett","year":"2024","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.jcyt.2025.04.064_bib0175","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1093\/neuonc\/noad087","article-title":"Intracranial injection of natural killer cells engineered with a HER2-targeted chimeric antigen receptor in patients with recurrent glioblastoma","volume":"25","author":"Burger","year":"2023","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.jcyt.2025.04.064_bib0176","doi-asserted-by":"crossref","first-page":"7209","DOI":"10.1182\/blood-2024-202988","article-title":"Safety and feasibility of a 41BB co-stimulated CD19 CAR-NK cell therapy in refractory\/relapsed large B-cell lymphoma","volume":"144","author":"Qian","year":"2024","journal-title":"Blood"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324925006875?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324925006875?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T21:17:54Z","timestamp":1755551874000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324925006875"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":176,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S1465324925006875"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2025.04.064","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dark NKnight rising: a current perspective on NK cell and CAR-NK cell therapy","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2025.04.064","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Society for Cell & Gene Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}